Jump to content


from my inquiry on the "other" forum

  • Please log in to reply
21 replies to this topic

#21 Buzzm1


    Advanced Member

  • Members
  • PipPipPip
  • 972 posts
  • LocationSilicon Valley

Posted 08 February 2016 - 11:23 PM

Experts reveal 'troubling' industry-employed strategies to delay availability of generic cancer drugs http://goo.gl/65KGvW


"Because of these arrangements and perceived 'oligopolies' that persist for another 6 months, the generic company was able to set the price of the generic at 70% of the patented price for an additional 6 months," Kantarjian said. "The yearly cost of imatinib is around $130,000, so the generic cost will be about $90,000, which is what the patented drug cost us just 2 years ago. Moreover, the effective additional 1 year of high drug price extension will cost the U.S. health care system up to $3 billion for this one drug, and prevent thousands of patients from having access to an affordable drug."


The Federal Trade Commission has estimated that pay-for-delay settlements cost taxpayers, consumers and insurance companies approximately $3.5 billion per year. The U.S. Supreme Court and state Supreme Courts have posited that these payments could violate antitrust statutes.


Novartis Imatinib (Gleevec) Pricing

$24K/yr. 2001 intro
$132K/yr 08/2015
U.S. generic available 02/01/2016 will cost  almost 4 times the original 2001 price

Novartis's greed sucks; the cost of generic Gleevec elsewhere http://bit.ly/1vvuCg3


R&D costs for Gleevec http://keionline.org/node/1697

The "genius" of BIG PhRMA is in buying votes in Congress ..
BIG PhRMA is the highest spending Lobby in Washington DC 
Senate Health, Education, Labor, and Pensions Committee http://bit.ly/11EEmWL
House Oversight and Government Reform Committee http://bit.ly/1L7Qek9
all of Congress http://bit.ly/1a2QiUB

For the benefit of yourself and others please add your CML history into your Signature


02/2010 Gleevec 400mg

2011 Two weakly positives, PCRU, weakly positive


2013 PCRU, PCRU, PCRU, weakly positive

2014 PCRU, PCRU, PCRU, PCRU (12/07 began dose reduction w/each continuing PCRU)

2015 300, 250, 200, 150

2016 100, 50/100, 100, 10/17 TFR

2017 01/17 TFR, 04/18 TFR, 07/18 TFR 0.0012, 08/29 TFR 0.001, 10/17 TFR 0.000

2018 01/16 TFR 0.0004 ... next quarterly PCR 04/17


At the earliest opportunity, and whenever possible, lower your TKI dosage; TKIs are toxic drugs and the less we take longterm the better off we are going to be ... this is especially true for older adults.  


In hindsight I should have started my dosage reduction two years earlier; it might have helped minimize some of the longterm cumulative toxic effects of TKIs that I am beset with.  


longterm side-effects Peripheral Artery Disease - legs (it's a bitch); continuing shoulder problems, right elbow inflammation.   GFR and creatinine vastly improved after stopping Gleevec.


Cumulative Gleevec dosage estimated at 830 grams


Taking Gleevec 400mg an hour after my largest meal of the day helped eliminate the nausea that Gleevec is notorious for.  


Trey's CML BlogStopping - The OddsStop Studies - Discussion Forum Cessation Study

Big PhRMA - Medicare Status - Social Security Status - Deficit/Debt

#22 Kali


    Advanced Member

  • Members
  • PipPipPip
  • 112 posts

Posted 09 February 2016 - 10:04 AM

Thank you for sharing this article from Dr. Kantarjian. He sounds like a wonderful person with the greater good of mankind in his heart. The condition of the heart speaks volumes about the actions of human beings.

This was a great article. With more people like him, there is some hope perhaps. It is so good to know he is speaking truth to this painful problem that exists.

Diagnosed June 2014. WBC 34.6 and Platelets 710 at diagnosis. Bone Marrow Biopsy pre-op diagnosis: Leukocytosis. Post-op diagnosis: the same, Leukocytosis. No increase in blasts <1%. Quantitative BCR/ABL testing and formal chromosome analyses confirmed CML diagnosis.<p>Supplemental Report: Abnormal BCR/ABL1 FISH result t(9;22). Molecular test for BCR/ABL1 fusion transcript by RT-PCR positive for BCR/ABL1 transcripts, b3a2 at 133.561% and b2a2 at 0.001% and ela2 at 0.001%. Followup monitoring showed negative for ela2. BCRABL1 was 148.007 at diagnosis. Started Sprycel 100 mgm and blood work was normal at 3 weeks. MMR at 3 months: 10/4/14 was 0.106. Stayed in that range with one dip to 0.04 once and back to 0.1 range. Oct. 2015, BCRABL1 was not detected, following with 0.0126, 0.0092, <0.0069, 0.0000, <0.0069, 0.0000. Now on 70 mgm of Sprycel. Continuation of PCR test results: 07/07/2017, 0.0000%, now on 50 mgm of Sprycel, PCR 9/12/17 0.0074%, PCR 11/3/17 0.0000%, PCR 1/17/2018 0.0000%

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users